Imagine my excitement when I saw that there was a new colon cancer test being used! EndoNurse reported that New York's Department of Health has approved Quest Diagnostics's ColoVantage colorectal cancer detection method.
Senior vice president and chief medical officer of Quest Diagnostics, Jon R. Cohen, MD, says, "ColoVantage is a convenient, noninvasive option for the millions of patients 50 years of age and older who resist testing by recommended screening methods. As a technique that patients may actually use, ColoVantage is arguably the first practical testing option to promote meaningful cancer evaluation among this large underserved population."
Unlike other colorectal cancer screening tests, ColoVantage doesn't restrict diet or require special preparations. Also, testing can be added to routine blood work.
In a clinical study, ColoVantage correctly identified colorectal cancer in 70% of samples of people diagnosed with the cancer. Furthermore, it correctly detected the absence of colorectal cancer in approximately 89% of samples tested.
ColoVantage was released in December 2009. New York is the only state with an independent regulatory review process for tests developed in a laboratory, which are also regulated federally. With this approval, the ColoVantage can be offered in New York and the rest of the United States.
See, guys? We're just one step closer to more accurate and non-invasive colorectal cancer screenings!
(Picture Credit: PRLog)